(CRMD) CorMedix - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 613m USD | Total Return: -34.9% in 12m
Avg Turnover: 8.82M
Qual. Beats: 0
Rev. Trend: 97.1%
Qual. Beats: 1
Warnings
Earnings expected to drop: P/E 3.6 → Forward 15.3
Share dilution 34.8% YoY
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Below Avwap Earnings
Tailwinds
No distinct edge detected
CorMedix Inc. is a New Jersey-based biopharmaceutical company specializing in the commercialization of therapeutic products for life-threatening conditions. The company’s primary focus is DefenCath, an antimicrobial catheter lock solution designed to lower the frequency of bloodstream infections in adult patients undergoing hemodialysis for kidney failure.
The company operates within the specialized pharmaceutical sector, where high barriers to entry exist due to rigorous FDA clinical trial requirements and the complex logistics of medical device integration. CorMedix follows a targeted commercialization model, focusing on the dialysis market where catheter-related infections represent a significant cause of patient morbidity and healthcare costs.
For more detailed insights into the company’s financial health and valuation metrics, consider reviewing the comprehensive data available on ValueRay.
- DefenCath commercial launch and inpatient reimbursement success drive near-term revenue growth
- Expansion into outpatient dialysis market remains critical for long-term scalability
- FDA regulatory compliance at manufacturing facilities impacts production and supply stability
- High cash burn rate necessitates potential future equity dilutive financing rounds
- Strategic partnerships with dialysis providers determine market penetration and adoption rates
| Net Income: 181.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.24 > 0.02 and ΔFCF/TA 33.19 > 1.0 |
| NWC/Revenue: 63.58% < 20% (prev 133.8%; Δ -70.24% < -1%) |
| CFO/TA 0.24 > 3% & CFO 197.7m > Net Income 181.0m |
| Net Debt (-28.9m) to EBITDA (220.7m): -0.13 < 3 |
| Current Ratio: 2.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (93.0m) vs 12m ago 34.81% < -2% |
| Gross Margin: 85.83% > 18% (prev 0.95%; Δ 8.49k% > 0.5%) |
| Asset Turnover: 82.89% > 50% (prev 55.19%; Δ 27.70% > 0%) |
| Interest Coverage Ratio: 70.64 > 6 (EBITDA TTM 220.7m / Interest Expense TTM 2.77m) |
| A: 0.31 (Total Current Assets 383.1m - Total Current Liabilities 128.8m) / Total Assets 815.6m |
| B: -0.17 (Retained Earnings -138.0m / Total Assets 815.6m) |
| C: 0.41 (EBIT TTM 195.8m / Avg Total Assets 482.6m) |
| D: -0.36 (Book Value of Equity -137.9m / Total Liabilities 378.6m) |
| Altman-Z'' = 3.84 = AA |
| DSRI: 0.58 (Receivables 154.8m/54.6m, Revenue 400.1m/82.6m) |
| GMI: 1.11 (GM 85.83% / 95.19%) |
| AQI: 30.79 (AQ_t 0.52 / AQ_t-1 0.02) |
| SGI: 4.85 (Revenue 400.1m / 82.6m) |
| TATA: -0.02 (NI 181.0m - CFO 197.7m) / TA 815.6m) |
| Beneish M = 17.13 (Cap -4..+1) = D |
As of May 24, 2026, the stock is trading at USD 8.06 with a total of 1,318,375 shares traded.
Over the past week, the price has changed by +5.70%,
over one month by +6.54%,
over three months by +13.84% and
over the past year by -34.91%.
CorMedix has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy CRMD.
- StrongBuy: 3
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15 | 86.1% |
P/E Forward = 15.3374
P/S = 1.5335
P/B = 1.4037
Revenue TTM = 400.1m USD
EBIT TTM = 195.8m USD
EBITDA TTM = 220.7m USD
Long Term Debt = 144.9m USD (from longTermDebt, last quarter)
Short Term Debt = 1.45m USD (from shortTermDebt, last fiscal year)
Debt = 149.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.29m
Net Debt = -28.9m USD (calculated: Debt 149.2m - CCE 178.1m)
Enterprise Value = 584.6m USD (613.5m + Debt 149.2m - CCE 178.1m)
Interest Coverage Ratio = 70.64 (Ebit TTM 195.8m / Interest Expense TTM 2.77m)
EV/FCF = 2.98x (Enterprise Value 584.6m / FCF TTM 196.4m)
FCF Yield = 33.59% (FCF TTM 196.4m / Enterprise Value 584.6m)
FCF Margin = 49.09% (FCF TTM 196.4m / Revenue TTM 400.1m)
Net Margin = 45.25% (Net Income TTM 181.0m / Revenue TTM 400.1m)
Gross Margin = 85.83% ((Revenue TTM 400.1m - Cost of Revenue TTM 56.7m) / Revenue TTM)
Gross Margin QoQ = 82.50% (prev 83.43%)
Tobins Q-Ratio = 0.72 (Enterprise Value 584.6m / Total Assets 815.6m)
Interest Expense / Debt = 1.86% (Interest Expense 2.77m / Debt 149.2m)
Taxrate = 30.63% (17.0m / 55.6m)
NOPAT = 135.8m (EBIT 195.8m * (1 - 30.63%))
Current Ratio = 2.98 (Total Current Assets 383.1m / Total Current Liabilities 128.8m)
Debt / Equity = 0.34 (Debt 149.2m / totalStockholderEquity, last quarter 437.0m)
Debt / EBITDA = -0.13 (Net Debt -28.9m / EBITDA 220.7m)
Debt / FCF = -0.15 (Net Debt -28.9m / FCF TTM 196.4m)
Total Stockholder Equity = 359.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 37.51% (Net Income 181.0m / Total Assets 815.6m)
RoE = 36.40% (Net Income TTM 181.0m / Total Stockholder Equity 497.3m)
RoCE = 30.49% (EBIT 195.8m / Capital Employed (Equity 497.3m + L.T.Debt 144.9m))
RoIC = 26.62% (NOPAT 135.8m / Invested Capital 510.2m)
WACC = 8.35% (E(613.5m)/V(762.7m) * Re(10.07%) + D(149.2m)/V(762.7m) * Rd(1.86%) * (1-Tc(0.31)))
Discount Rate = 10.07% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 23.92%
[DCF] Terminal Value 75.43% ; FCFF base≈196.4m ; Y1≈197.2m ; Y5≈208.9m
[DCF] Fair Price = 41.77 (EV 3.25b - Net Debt -28.9m = Equity 3.28b / Shares 78.5m; r=8.35% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.04 | # QB: 0
Revenue Correlation: 97.10 | Revenue CAGR: 4.63k% | SUE: 3.67 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.27 | Chg30d=-3.64% | Revisions=+20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.07 | Chg30d=-21.05% | Revisions=N/A | Analysts=2
EPS current Year (2026-12-31): EPS=0.97 | Chg30d=+20.50% | Revisions=-20% | GrowthEPS=-54.8% | GrowthRev=+7.3%
EPS next Year (2027-12-31): EPS=0.80 | Chg30d=+9.59% | Revisions=-20% | GrowthEPS=-17.5% | GrowthRev=-10.8%
[Analyst] Revisions Ratio: +20%